Effectiveness of Anti-SARS-CoV-2 monoclonal antibodies in real-life: RNAemia and clinical outcomes in high-risk COVID-19 patients
Early administration of anti-SARS-CoV-2 mAbs in high-risk patients significantly reduced viral loads in NPS and plasma and improved clinical outcomes. Despite the presence of RNAemia, these tailored mAb therapies led to favorable recovery times and minimal adverse effects.
Authors
- Francesca Bai (ORCID: https://orcid.org/0000-0002-3651-8923)
- Silvia Ancona (ORCID: https://orcid.org/0000-0003-1999-129X)
- Emerenziana Ottaviano (ORCID: https://orcid.org/0000-0003-3839-2698)
- Elisa Borghi (ORCID: https://orcid.org/0000-0002-1893-0455)
- Silvia Bianchi (ORCID: https://orcid.org/0000-0002-1365-9408)
- Camilla Tincati (ORCID: https://orcid.org/0000-0002-3083-2962)
- Giulia Marchetti (ORCID: https://orcid.org/0000-0002-4498-4828)
- Matteo Domenico Marsiglia (ORCID: https://orcid.org/0009-0009-3421-9223)
Institutions
- AOL (United States) (US)
- University of Milan (IT)
- Ospedale San Paolo (IT)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1371/journal.pone.0321356
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00